Key clinical point: Tirzepatide. at doses of  10 or 15 mg, vs. 2 mg semaglutide was associated with a significantly greater reduction in glycated hemoglobin (A1c) levels and body weight in patients with type 2 diabetes (T2D). Both drugs had a similar overall safety profile.

Major finding: At week 40, 10 and 15 mg tirzepatide vs. 2 mg semaglutide led to a significantly greater reduction in A1c levels (estimated treatment difference [ETD] −0.36%; P = .008, and ETD −0.4%; P = .003, respectively) and body weight (ETD −3.15 and −5.15 kg, respectively; both P < .001).

Study details: This was an adjusted indirect treatment comparison study that included patients with T2D from the SURPASS-2 (n = 1879) and SUSTAIN FORTE (n = 961) trials who were randomly assigned to receive tirzepatide or injectable semaglutide.

Disclosures: This study was funded by Eli Lilly and Company. Two authors declared being advisory board members or receiving speaking or consulting honoraria or research support from various sources, including Eli Lilly. The other authors are employees and shareholders of Eli Lilly.

Source: Vadher K et al. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes Obes Metab. 2022 (May 19). Doi: 10.1111/dom.14775

Key clinical point: Tirzepatide. at doses of  10 or 15 mg, vs. 2 mg semaglutide was associated with a significantly greater reduction in glycated hemoglobin (A1c) levels and body weight in patients with type 2 diabetes (T2D). Both drugs had a similar overall safety profile.

Major finding: At week 40, 10 and 15 mg tirzepatide vs. 2 mg semaglutide led to a significantly greater reduction in A1c levels (estimated treatment difference [ETD] −0.36%; P = .008, and ETD −0.4%; P = .003, respectively) and body weight (ETD −3.15 and −5.15 kg, respectively; both P < .001).

Study details: This was an adjusted indirect treatment comparison study that included patients with T2D from the SURPASS-2 (n = 1879) and SUSTAIN FORTE (n = 961) trials who were randomly assigned to receive tirzepatide or injectable semaglutide.

Disclosures: This study was funded by Eli Lilly and Company. Two authors declared being advisory board members or receiving speaking or consulting honoraria or research support from various sources, including Eli Lilly. The other authors are employees and shareholders of Eli Lilly.

Source: Vadher K et al. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes Obes Metab. 2022 (May 19). Doi: 10.1111/dom.14775

Key clinical point: Tirzepatide. at doses of  10 or 15 mg, vs. 2 mg semaglutide was associated with a significantly greater reduction in glycated hemoglobin (A1c) levels and body weight in patients with type 2 diabetes (T2D). Both drugs had a similar overall safety profile.

Major finding: At week 40, 10 and 15 mg tirzepatide vs. 2 mg semaglutide led to a significantly greater reduction in A1c levels (estimated treatment difference [ETD] −0.36%; P = .008, and ETD −0.4%; P = .003, respectively) and body weight (ETD −3.15 and −5.15 kg, respectively; both P < .001).

Study details: This was an adjusted indirect treatment comparison study that included patients with T2D from the SURPASS-2 (n = 1879) and SUSTAIN FORTE (n = 961) trials who were randomly assigned to receive tirzepatide or injectable semaglutide.

Disclosures: This study was funded by Eli Lilly and Company. Two authors declared being advisory board members or receiving speaking or consulting honoraria or research support from various sources, including Eli Lilly. The other authors are employees and shareholders of Eli Lilly.

Source: Vadher K et al. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes Obes Metab. 2022 (May 19). Doi: 10.1111/dom.14775

Key clinical point: In patients with type 2 diabetes (T2D), once-weekly tirzepatide demonstrated dose-dependent superiority on glycemic efficacy vs. placebo, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), and basal insulin, without increasing the chances of hypoglycemia.

Major finding: Tirzepatide, at does of 5, 10, and 15 mg, was more effective than placebo in reducing glycated hemoglobin levels, with mean differences (95% CI) being −17.71 (−21.66 to −13.75), −20.20 (−22.90 to −17.51), and −22.35 (−26.09 to −18.62) mmol/mol, respectively. Similar findings were recorded for tirzepatide vs. GLP-1 RA or basal insulin. The incidence of hypoglycemia was not significantly different between the treatment groups.

Study details: The data come from a meta-analysis of seven randomized controlled trials including 6609 patients with T2D.

Disclosures: The study received no specific funding. Some authors declared receiving research grants, consulting fees, research support, or honoraria from, or serving as consultants or advisory board members for various sources.

Source: Karagiannis T et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis. Diabetologia. 2022 (May 17). Doi: 10.1007/s00125-022-05715-4

Key clinical point: In patients with type 2 diabetes (T2D), once-weekly tirzepatide demonstrated dose-dependent superiority on glycemic efficacy vs. placebo, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), and basal insulin, without increasing the chances of hypoglycemia.

Major finding: Tirzepatide, at does of 5, 10, and 15 mg, was more effective than placebo in reducing glycated hemoglobin levels, with mean differences (95% CI) being −17.71 (−21.66 to −13.75), −20.20 (−22.90 to −17.51), and −22.35 (−26.09 to −18.62) mmol/mol, respectively. Similar findings were recorded for tirzepatide vs. GLP-1 RA or basal insulin. The incidence of hypoglycemia was not significantly different between the treatment groups.

Study details: The data come from a meta-analysis of seven randomized controlled trials including 6609 patients with T2D.

Disclosures: The study received no specific funding. Some authors declared receiving research grants, consulting fees, research support, or honoraria from, or serving as consultants or advisory board members for various sources.

Source: Karagiannis T et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis. Diabetologia. 2022 (May 17). Doi: 10.1007/s00125-022-05715-4

Key clinical point: In patients with type 2 diabetes (T2D), once-weekly tirzepatide demonstrated dose-dependent superiority on glycemic efficacy vs. placebo, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), and basal insulin, without increasing the chances of hypoglycemia.

Major finding: Tirzepatide, at does of 5, 10, and 15 mg, was more effective than placebo in reducing glycated hemoglobin levels, with mean differences (95% CI) being −17.71 (−21.66 to −13.75), −20.20 (−22.90 to −17.51), and −22.35 (−26.09 to −18.62) mmol/mol, respectively. Similar findings were recorded for tirzepatide vs. GLP-1 RA or basal insulin. The incidence of hypoglycemia was not significantly different between the treatment groups.

Study details: The data come from a meta-analysis of seven randomized controlled trials including 6609 patients with T2D.

Disclosures: The study received no specific funding. Some authors declared receiving research grants, consulting fees, research support, or honoraria from, or serving as consultants or advisory board members for various sources.

Source: Karagiannis T et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis. Diabetologia. 2022 (May 17). Doi: 10.1007/s00125-022-05715-4

Key clinical point: The antepartum 75g-oral glucose tolerance test (75g-OGTT) can identify nulliparous pregnant women who are at risk of developing type 2 diabetes mellitus (T2D), even if they tested negative for gestational diabetes (GD).

Major finding: In women without GD, the fasting (adjusted hazard ratio [aHR] 2.82; 95% CI 2.18-3.64), 1-hour (aHR 1.26; 95% CI 1.15-1.37), and 2-hour (aHR 1.14; 95% CI 1.04-1.25) 75g-OGTT values were significantly associated with a future risk of developing T2D, with a model combining all three OGTT values and clinical characteristics being able to detect 43.7% (95% CI 43.2%-44.2%) of women who developed T2D at 5 years after the index pregnancy.

Study details: The data come from a retrospective study of 41,507 nulliparous pregnant women who tested negative for GD using a 75g-OGTT.

Disclosures: This study was funded by the Canadian Institute of Health Research. The authors report no conflicts of interest.

Source: Hiersch L et al. The prognostic value of the oral glucose tolerance test for future type-2 diabetes in nulliparous pregnant women testing negative for gestational diabetes. Diabetes Metab. 2022 (Jun 2). Doi: 10.1016/j.diabet.2022.101364

Key clinical point: The antepartum 75g-oral glucose tolerance test (75g-OGTT) can identify nulliparous pregnant women who are at risk of developing type 2 diabetes mellitus (T2D), even if they tested negative for gestational diabetes (GD).

Major finding: In women without GD, the fasting (adjusted hazard ratio [aHR] 2.82; 95% CI 2.18-3.64), 1-hour (aHR 1.26; 95% CI 1.15-1.37), and 2-hour (aHR 1.14; 95% CI 1.04-1.25) 75g-OGTT values were significantly associated with a future risk of developing T2D, with a model combining all three OGTT values and clinical characteristics being able to detect 43.7% (95% CI 43.2%-44.2%) of women who developed T2D at 5 years after the index pregnancy.

Study details: The data come from a retrospective study of 41,507 nulliparous pregnant women who tested negative for GD using a 75g-OGTT.

Disclosures: This study was funded by the Canadian Institute of Health Research. The authors report no conflicts of interest.

Source: Hiersch L et al. The prognostic value of the oral glucose tolerance test for future type-2 diabetes in nulliparous pregnant women testing negative for gestational diabetes. Diabetes Metab. 2022 (Jun 2). Doi: 10.1016/j.diabet.2022.101364

Key clinical point: The antepartum 75g-oral glucose tolerance test (75g-OGTT) can identify nulliparous pregnant women who are at risk of developing type 2 diabetes mellitus (T2D), even if they tested negative for gestational diabetes (GD).

Major finding: In women without GD, the fasting (adjusted hazard ratio [aHR] 2.82; 95% CI 2.18-3.64), 1-hour (aHR 1.26; 95% CI 1.15-1.37), and 2-hour (aHR 1.14; 95% CI 1.04-1.25) 75g-OGTT values were significantly associated with a future risk of developing T2D, with a model combining all three OGTT values and clinical characteristics being able to detect 43.7% (95% CI 43.2%-44.2%) of women who developed T2D at 5 years after the index pregnancy.

Study details: The data come from a retrospective study of 41,507 nulliparous pregnant women who tested negative for GD using a 75g-OGTT.

Disclosures: This study was funded by the Canadian Institute of Health Research. The authors report no conflicts of interest.

Source: Hiersch L et al. The prognostic value of the oral glucose tolerance test for future type-2 diabetes in nulliparous pregnant women testing negative for gestational diabetes. Diabetes Metab. 2022 (Jun 2). Doi: 10.1016/j.diabet.2022.101364

Key clinical point: Combination of metformin plus a low hypoglycemic risk antidiabetic drug provides better glycemic control than metformin monotherapy without increasing the risk for hypoglycemia in patients with untreated type 2 diabetes mellitus (T2D).

Major finding: Combination therapy vs. metformin monotherapy significantly reduced glycated hemoglobin (A1c) levels (mean difference [MD] −0.48%; P < .001) and fasting plasma glucose levels (MD −0.92 mmol/L; P < .001) and led to a higher proportion of patients achieving  an A1c level of <7% (odds ratio 2.21; P < .00001), without any significant increase in hypoglycemic events.

Study details: Findings are from a meta-analysis of 14 randomized controlled trials including 5316 patients with untreated T2D who were randomly assigned to receive combination therapy or metformin monotherapy.

Disclosures: This work was supported by Ministry of Science and Technology and Chang Gung Memorial Hospital, Taiwan. The authors declared no conflicts of interest.

Source: Hung WT et al. Metformin plus a low hypoglycemic risk antidiabetic drug vs. metformin monotherapy for untreated type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2022;189:10937 (Jun 1). Doi: 10.1016/j.diabres.2022.109937

Key clinical point: Combination of metformin plus a low hypoglycemic risk antidiabetic drug provides better glycemic control than metformin monotherapy without increasing the risk for hypoglycemia in patients with untreated type 2 diabetes mellitus (T2D).

Major finding: Combination therapy vs. metformin monotherapy significantly reduced glycated hemoglobin (A1c) levels (mean difference [MD] −0.48%; P < .001) and fasting plasma glucose levels (MD −0.92 mmol/L; P < .001) and led to a higher proportion of patients achieving  an A1c level of <7% (odds ratio 2.21; P < .00001), without any significant increase in hypoglycemic events.

Study details: Findings are from a meta-analysis of 14 randomized controlled trials including 5316 patients with untreated T2D who were randomly assigned to receive combination therapy or metformin monotherapy.

Disclosures: This work was supported by Ministry of Science and Technology and Chang Gung Memorial Hospital, Taiwan. The authors declared no conflicts of interest.

Source: Hung WT et al. Metformin plus a low hypoglycemic risk antidiabetic drug vs. metformin monotherapy for untreated type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2022;189:10937 (Jun 1). Doi: 10.1016/j.diabres.2022.109937

Key clinical point: Combination of metformin plus a low hypoglycemic risk antidiabetic drug provides better glycemic control than metformin monotherapy without increasing the risk for hypoglycemia in patients with untreated type 2 diabetes mellitus (T2D).

Major finding: Combination therapy vs. metformin monotherapy significantly reduced glycated hemoglobin (A1c) levels (mean difference [MD] −0.48%; P < .001) and fasting plasma glucose levels (MD −0.92 mmol/L; P < .001) and led to a higher proportion of patients achieving  an A1c level of <7% (odds ratio 2.21; P < .00001), without any significant increase in hypoglycemic events.

Study details: Findings are from a meta-analysis of 14 randomized controlled trials including 5316 patients with untreated T2D who were randomly assigned to receive combination therapy or metformin monotherapy.

Disclosures: This work was supported by Ministry of Science and Technology and Chang Gung Memorial Hospital, Taiwan. The authors declared no conflicts of interest.

Source: Hung WT et al. Metformin plus a low hypoglycemic risk antidiabetic drug vs. metformin monotherapy for untreated type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2022;189:10937 (Jun 1). Doi: 10.1016/j.diabres.2022.109937

Key clinical point: Patients with type 2 diabetes (T2D) who initiated first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i) vs. metformin showed a similar risk for hospitalization for myocardial infarction (MI)/stroke or all-cause mortality, a lower risk for hospitalization for heart failure (HHF) or all-cause mortality, and a similar safety profile, except for an increased risk for genital infections.

Major finding: Patients initiating the first-line treatment with SGLT-2i vs. metformin had a similar risk for MI/stroke/mortality (hazard ratio[HR] 0.96; 95% CI 0.77-1.19), a lower risk for HHF/mortality (HR 0.80; 95% CI 0.66-0.97), and a similar safety profile, except for an increased risk for genital infections (HR 2.19; 95% CI 1.91-2.51).

Study details: This population-based cohort study included 8613 patients with T2D initiating SGLT-2i and 17,226 matched patients initiating metformin.

Disclosures: This study was funded by the Brigham and Women's Hospital and Harvard Medical School. RJ Glynn, E Patorno, and S Schneeweiss declared receiving research grants or consulting fees, serving on advisory boards, or holding stock or stock options for various sources.

Source: Shin H et al. Cardiovascular outcomes in patients initiating first-line treatment of type 2 diabetes with sodium–glucose cotransporter-2 inhibitors versus metformin: A cohort study. Ann Intern Med. 2022 (May 24). Doi: 10.7326/M21-4012

Key clinical point: Patients with type 2 diabetes (T2D) who initiated first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i) vs. metformin showed a similar risk for hospitalization for myocardial infarction (MI)/stroke or all-cause mortality, a lower risk for hospitalization for heart failure (HHF) or all-cause mortality, and a similar safety profile, except for an increased risk for genital infections.

Major finding: Patients initiating the first-line treatment with SGLT-2i vs. metformin had a similar risk for MI/stroke/mortality (hazard ratio[HR] 0.96; 95% CI 0.77-1.19), a lower risk for HHF/mortality (HR 0.80; 95% CI 0.66-0.97), and a similar safety profile, except for an increased risk for genital infections (HR 2.19; 95% CI 1.91-2.51).

Study details: This population-based cohort study included 8613 patients with T2D initiating SGLT-2i and 17,226 matched patients initiating metformin.

Disclosures: This study was funded by the Brigham and Women's Hospital and Harvard Medical School. RJ Glynn, E Patorno, and S Schneeweiss declared receiving research grants or consulting fees, serving on advisory boards, or holding stock or stock options for various sources.

Source: Shin H et al. Cardiovascular outcomes in patients initiating first-line treatment of type 2 diabetes with sodium–glucose cotransporter-2 inhibitors versus metformin: A cohort study. Ann Intern Med. 2022 (May 24). Doi: 10.7326/M21-4012

Key clinical point: Patients with type 2 diabetes (T2D) who initiated first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i) vs. metformin showed a similar risk for hospitalization for myocardial infarction (MI)/stroke or all-cause mortality, a lower risk for hospitalization for heart failure (HHF) or all-cause mortality, and a similar safety profile, except for an increased risk for genital infections.

Major finding: Patients initiating the first-line treatment with SGLT-2i vs. metformin had a similar risk for MI/stroke/mortality (hazard ratio[HR] 0.96; 95% CI 0.77-1.19), a lower risk for HHF/mortality (HR 0.80; 95% CI 0.66-0.97), and a similar safety profile, except for an increased risk for genital infections (HR 2.19; 95% CI 1.91-2.51).

Study details: This population-based cohort study included 8613 patients with T2D initiating SGLT-2i and 17,226 matched patients initiating metformin.

Disclosures: This study was funded by the Brigham and Women's Hospital and Harvard Medical School. RJ Glynn, E Patorno, and S Schneeweiss declared receiving research grants or consulting fees, serving on advisory boards, or holding stock or stock options for various sources.

Source: Shin H et al. Cardiovascular outcomes in patients initiating first-line treatment of type 2 diabetes with sodium–glucose cotransporter-2 inhibitors versus metformin: A cohort study. Ann Intern Med. 2022 (May 24). Doi: 10.7326/M21-4012

Key clinical point: Once-weekly dulaglutide was superior to placebo in improving glycemic control through 26 weeks in youths with inadequately controlled type 2 diabetes (T2D) who were being treated with or without metformin or basal insulin.

Major finding: At 26 weeks, 0.75 mg and 1.5 mg dulaglutide vs. placebo led to a significant reduction in mean glycated hemoglobin (A1c) level (estimated treatment difference −1.2% and −1.5%, respectively), in addition to a significant increase in the proportion of patients achieving an A1c level of <7.0% (all P < .001) and a consistent safety profile.

Study details: The data come from the AWARD-PEDS trial including 154 patients with T2D treated with lifestyle modification alone or metformin with or without basal insulin and who were randomly assigned to receive once-weekly dulaglutide or placebo for 26 weeks.

Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving grants or contracts or serving as consultants or on safety and data monitoring boards for various sources, including Eli Lilly. D Cox declared being an employee of and holding stocks or stock options in Eli Lilly.

Source: Arslanian SA et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022 (Jun 4). Doi: 10.1056/NEJMoa2204601

Key clinical point: Once-weekly dulaglutide was superior to placebo in improving glycemic control through 26 weeks in youths with inadequately controlled type 2 diabetes (T2D) who were being treated with or without metformin or basal insulin.

Major finding: At 26 weeks, 0.75 mg and 1.5 mg dulaglutide vs. placebo led to a significant reduction in mean glycated hemoglobin (A1c) level (estimated treatment difference −1.2% and −1.5%, respectively), in addition to a significant increase in the proportion of patients achieving an A1c level of <7.0% (all P < .001) and a consistent safety profile.

Study details: The data come from the AWARD-PEDS trial including 154 patients with T2D treated with lifestyle modification alone or metformin with or without basal insulin and who were randomly assigned to receive once-weekly dulaglutide or placebo for 26 weeks.

Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving grants or contracts or serving as consultants or on safety and data monitoring boards for various sources, including Eli Lilly. D Cox declared being an employee of and holding stocks or stock options in Eli Lilly.

Source: Arslanian SA et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022 (Jun 4). Doi: 10.1056/NEJMoa2204601

Key clinical point: Once-weekly dulaglutide was superior to placebo in improving glycemic control through 26 weeks in youths with inadequately controlled type 2 diabetes (T2D) who were being treated with or without metformin or basal insulin.

Major finding: At 26 weeks, 0.75 mg and 1.5 mg dulaglutide vs. placebo led to a significant reduction in mean glycated hemoglobin (A1c) level (estimated treatment difference −1.2% and −1.5%, respectively), in addition to a significant increase in the proportion of patients achieving an A1c level of <7.0% (all P < .001) and a consistent safety profile.

Study details: The data come from the AWARD-PEDS trial including 154 patients with T2D treated with lifestyle modification alone or metformin with or without basal insulin and who were randomly assigned to receive once-weekly dulaglutide or placebo for 26 weeks.

Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving grants or contracts or serving as consultants or on safety and data monitoring boards for various sources, including Eli Lilly. D Cox declared being an employee of and holding stocks or stock options in Eli Lilly.

Source: Arslanian SA et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022 (Jun 4). Doi: 10.1056/NEJMoa2204601

Key clinical point: A structured 12-month weight-loss treatment with very low energy diet (VLED) showed positive effects on body weight and physical fitness without affecting the muscle strength in patients with psoriatic arthritis (PsA) and obesity.

Major finding: At month 12, the median weight loss was 16.1 kg in patients with PsA and obesity and 16.6 kg in control individuals with obesity. At month 6, the muscle strength of the lower extremities and physical functioning improved in patients with PsA and control individuals (all P < .001), which were maintained till month 12 (all P < .01). The hand-grip strength remained unchanged in both the groups.

Study details: The findings are a secondary analysis of a prospective open intervention study including 46 patients with PsA and body mass index of ≥33 kg/m² and 52 matched control individuals with obesity, all of whom received weight-loss treatment with VLED.

Disclosures: This study was supported by the Swedish state, Health and Medical Care Executive Board of the Västra Götaland, and other sources. The authors declared no conflicts of interest.

Source: Bilberg A et al. The impact of a structured weight-loss treatment on physical fitness in patients with psoriatic arthritis and obesity compared to matched controls: a prospective interventional study. Clin Rheumatol. 2022 (Jun 1). Doi: 10.1007/s10067-022-06164-5

Key clinical point: A structured 12-month weight-loss treatment with very low energy diet (VLED) showed positive effects on body weight and physical fitness without affecting the muscle strength in patients with psoriatic arthritis (PsA) and obesity.

Major finding: At month 12, the median weight loss was 16.1 kg in patients with PsA and obesity and 16.6 kg in control individuals with obesity. At month 6, the muscle strength of the lower extremities and physical functioning improved in patients with PsA and control individuals (all P < .001), which were maintained till month 12 (all P < .01). The hand-grip strength remained unchanged in both the groups.

Study details: The findings are a secondary analysis of a prospective open intervention study including 46 patients with PsA and body mass index of ≥33 kg/m² and 52 matched control individuals with obesity, all of whom received weight-loss treatment with VLED.

Disclosures: This study was supported by the Swedish state, Health and Medical Care Executive Board of the Västra Götaland, and other sources. The authors declared no conflicts of interest.

Source: Bilberg A et al. The impact of a structured weight-loss treatment on physical fitness in patients with psoriatic arthritis and obesity compared to matched controls: a prospective interventional study. Clin Rheumatol. 2022 (Jun 1). Doi: 10.1007/s10067-022-06164-5

Key clinical point: A structured 12-month weight-loss treatment with very low energy diet (VLED) showed positive effects on body weight and physical fitness without affecting the muscle strength in patients with psoriatic arthritis (PsA) and obesity.

Major finding: At month 12, the median weight loss was 16.1 kg in patients with PsA and obesity and 16.6 kg in control individuals with obesity. At month 6, the muscle strength of the lower extremities and physical functioning improved in patients with PsA and control individuals (all P < .001), which were maintained till month 12 (all P < .01). The hand-grip strength remained unchanged in both the groups.

Study details: The findings are a secondary analysis of a prospective open intervention study including 46 patients with PsA and body mass index of ≥33 kg/m² and 52 matched control individuals with obesity, all of whom received weight-loss treatment with VLED.

Disclosures: This study was supported by the Swedish state, Health and Medical Care Executive Board of the Västra Götaland, and other sources. The authors declared no conflicts of interest.

Source: Bilberg A et al. The impact of a structured weight-loss treatment on physical fitness in patients with psoriatic arthritis and obesity compared to matched controls: a prospective interventional study. Clin Rheumatol. 2022 (Jun 1). Doi: 10.1007/s10067-022-06164-5

Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).

Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).

Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi:  10.1155/2022/4433313

Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).

Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).

Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi:  10.1155/2022/4433313

Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).

Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).

Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi:  10.1155/2022/4433313

Key clinical point: Inflammatory and metabolic parameters, including visceral adiposity, potentially contribute to subclinical coronary artery disease (CAD) in patients with psoriatic arthritis (PsA).

Major finding: CAD was significantly associated with visceral adiposity (standardized β 0.681; P = .002), and fluorodeoxyglucose (FDG) uptake in the bone marrow (standardized β 0.488; P = .008), liver (standardized β 0.619; P < .001), spleen (standardized β 0.523; P = .004), and subcutaneous adipose tissue (standardized β 0.524; P = .003). Visceral (P = .005) and subcutaneous (P = .004) adiposity and liver FDG uptake (P = .03) were higher in patients with PsA vs. controls without PsA.

Study details: Findings are from a cross-sectional analysis of a prospective study including 39 patients with biologic-naive PsA and 56 age-sex matched controls without PsA.

Disclosures: This study was funded by the US National Institute of Allergy and Infectious Disease, the US National Heart, Lung, and Blood Institute, and National Psoriasis Foundation. N Mehta declared serving as consultant and receiving grants and other payments from several sources.

Source: Schwartz DM et al. PET/CT-based characterization of 18F-FDG uptake in various tissues reveals novel potential contributions to coronary artery disease in psoriatic arthritis. Front Immunol. 2022;13:909760 (Jun 2). Doi: 10.3389/fimmu.2022.909760

Key clinical point: Inflammatory and metabolic parameters, including visceral adiposity, potentially contribute to subclinical coronary artery disease (CAD) in patients with psoriatic arthritis (PsA).

Major finding: CAD was significantly associated with visceral adiposity (standardized β 0.681; P = .002), and fluorodeoxyglucose (FDG) uptake in the bone marrow (standardized β 0.488; P = .008), liver (standardized β 0.619; P < .001), spleen (standardized β 0.523; P = .004), and subcutaneous adipose tissue (standardized β 0.524; P = .003). Visceral (P = .005) and subcutaneous (P = .004) adiposity and liver FDG uptake (P = .03) were higher in patients with PsA vs. controls without PsA.

Study details: Findings are from a cross-sectional analysis of a prospective study including 39 patients with biologic-naive PsA and 56 age-sex matched controls without PsA.

Disclosures: This study was funded by the US National Institute of Allergy and Infectious Disease, the US National Heart, Lung, and Blood Institute, and National Psoriasis Foundation. N Mehta declared serving as consultant and receiving grants and other payments from several sources.

Source: Schwartz DM et al. PET/CT-based characterization of 18F-FDG uptake in various tissues reveals novel potential contributions to coronary artery disease in psoriatic arthritis. Front Immunol. 2022;13:909760 (Jun 2). Doi: 10.3389/fimmu.2022.909760

Key clinical point: Inflammatory and metabolic parameters, including visceral adiposity, potentially contribute to subclinical coronary artery disease (CAD) in patients with psoriatic arthritis (PsA).

Major finding: CAD was significantly associated with visceral adiposity (standardized β 0.681; P = .002), and fluorodeoxyglucose (FDG) uptake in the bone marrow (standardized β 0.488; P = .008), liver (standardized β 0.619; P < .001), spleen (standardized β 0.523; P = .004), and subcutaneous adipose tissue (standardized β 0.524; P = .003). Visceral (P = .005) and subcutaneous (P = .004) adiposity and liver FDG uptake (P = .03) were higher in patients with PsA vs. controls without PsA.

Study details: Findings are from a cross-sectional analysis of a prospective study including 39 patients with biologic-naive PsA and 56 age-sex matched controls without PsA.

Disclosures: This study was funded by the US National Institute of Allergy and Infectious Disease, the US National Heart, Lung, and Blood Institute, and National Psoriasis Foundation. N Mehta declared serving as consultant and receiving grants and other payments from several sources.

Source: Schwartz DM et al. PET/CT-based characterization of 18F-FDG uptake in various tissues reveals novel potential contributions to coronary artery disease in psoriatic arthritis. Front Immunol. 2022;13:909760 (Jun 2). Doi: 10.3389/fimmu.2022.909760

Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.

Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.

Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719

Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.

Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.

Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719

Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.

Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.

Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719